FDA orphan products development
Executive Summary
Former Center for Biologics Evaluation & Research Office of Cellular, Tissue & Gene Therapies Acting Director Phil Noguchi, MD, will leave FDA at the end of August. Noguchi has held the position of medical officer within the Office of Orphan Products Development since May (1"The Pink Sheet" May 17, 2004, In Brief)...
You may also be interested in...
FDA orphan drugs staff
Former Center for Biologics Evaluation & Research Office of Cellular, Tissue & Gene Therapies Acting Director Phil Noguchi, MD, joins Office of Orphan Products Development as medical reviewer. Joyce Frey-Vasconcells assumes acting director post at CBER's cell therapies office...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.